(EN) A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
CCTG GA4
NCT06043427
 Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Estomac
Oesophage |
Dr Mustapha Tehfé
Chantal Gosselin
514-890-8000 poste 24892
|
(EN) A Randomized, Phase ? Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer
ARTEMIDE-Gastric01
NCT06764875
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Estomac |
Dre Sara Soldera
|
(EN) A Randomized, Phase ? Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer
ARTEMIDE-Gastric01
NCT06764875
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Estomac |
Dr Maxime Chénard-Poirier
Maryse Gingras
418-691-5781
|
(EN) A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
CCTG GA4
NCT06043427
Actif en recrutement
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Estomac
Oesophage |
Dre Setareh Samimi
Marie-Anne Capobianco
514-338-2222 poste 3493
|
(EN) A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
TroFuse-015
NCT06356311
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Estomac
Oesophage |
Dre Sara Soldera
|
Groupe d'étude en oncologie du Québec